Protective effect of a muramyl dipeptide analog encapsulated in or mixed with liposomes against Candida albicans infection

No abstract is available for this paper.

• Publication year

  1983

• Venue

  Infection and Immunity

• Publication date

  1983-01-01

• Fields of study

  Biology, Medicine

• Identifiers
  DOI 10.1128/iai.39.1.172-178.1983PMID 6337095PMCID PMC347921
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• Correlation between in vivo anti-Pseudomonas and anti-Candida activities and clearance of carbon by the reticuloendothelial system for various muramyl dipeptide analogs, using normal and immunosuppressed mice

  1982cited by this paper
• Involvement of macrophages in the eradication of established metastases following intravenous injection of liposomes containing macrophage activators.

  1982cited by this paper
• Altered pharmacological properties of liposome-associated human interferon-alpha

  1982cited by this paper
• In vitro activation of tumoricidal properties in rat alveolar macrophages by synthetic muramyl dipeptide encapsulated in liposomes.

  1981cited by this paper
• Protective effect of muramyl dipeptide analogs against infections of Pseudomonas aeruginosa or Candida albicans in mice

  1981cited by this paper
• Eradication of spontaneous metastases and activation of alveolar macrophages by intravenous injection of liposomes containing muramyl dipeptide.

  1981cited by this paper
• Activation of macrophages for enhanced release of superoxide anion and greater killing of Candida albicans by injection of muramyl dipeptide

  1980cited by this paper
• Increased production of superoxide anion by macrophages exposed in vitro to muramyl dipeptide or lipopolysaccharide

  1980cited by this paper
• Relative enhancement by various liposomes of BCNU effectiveness against L-1210 leukemia in vivo.

  1980cited by this paper
• Components of mycobacteria and muramyl dipeptide with adjuvant activity induce lymphocyte activating factor.

  1980cited by this paper
• Muramyl dipeptide stimulation of particle clearance in several animal species.

  1980cited by this paper
• The comparative effects of isoprinosine, levamisole, muramyl dipeptide and SM1213 on lymphocyte and macrophage proliferation and activation in vitro.

  1979cited by this paper
• Direct augmentation of cytolytic activity of tumor-derived macrophages and macrophage cell lines by muramyl dipeptide.

  1979cited by this paper
• Stimulation of the reticuloendothelial system of mice by muramyl dipeptide

  1979cited by this paper
• Macrophage activation by bacterial cell walls and related synthetic compounds

  1979cited by this paper
• Fate of the synthetic immunoadjuvant, muramyl dipeptide (14C-labelled) in the mouse.

  1979cited by this paper
• Macrophage activation by mycobacterial water soluble compounds and synthetic muramyl dipeptide.

  1979cited by this paper
• Inhibition of macrophage migration by synthetic muramyl dipeptide.

  1978cited by this paper
• Interactions of liposomes with mammalian cells.

  1978cited by this paper
• The introduction of enzymes into cells by means of liposomes.

  1978cited by this paper
• PROPERTIES AND BIOLOGICAL EFFECTS OF LIPOSOMES AND THEIR USES IN PHARMACOLOGY AND TOXICOLOGY

  1978cited by this paper
• Comparison between macrophage activation and enhancement of nonspecific resistance to tumors by mycobacterial immunoadjuvants.

  1975cited by this paper

• Effect of •ôNH•ôN•ôNS•ô-Acetylchito-Oligosaccharides on Activation of Phagocytes

  2007cites this paper
• Problems in Antifungal Chemotherapy

  2005cites this paper
• Stimulation of nonspecific immunity, haemopoiesis and protection of mice against radiation injury by 1-adamantylamide-L-alanyl-D-isoglutamine incorporated in liposomes.

  2001cites this paper
• Stimulatory effects of extracellular products of mycobacterium spp. and various adjuvants on non‐specific immune response of Nile Tilapia, oreochromis nilotica

  2000cites this paper
• Interactions between cationic liposomes and bacteria: the physical-chemistry of the bactericidal action.

  1999cites this paper
• Immunomodulative effect of muramyldipeptide in mice with larval toxocarosis

  1999cites this paper
• Non-specific immune response of Nile tilapia, Oreochromis nilotica, to the extracellular products of Mycobacterium spp. and to various adjuvants.

  1998cites this paper
• Single-Organism Model of Host Defense against Infection: A Novel Immunotoxicologic Approach to Evaluate Immunomodulatory Drugs

  1997cites this paper
• ENHANCEMENT OF NONSPECIFIC RESISTANCE BY LIPOSOME ENCAPSULATED IMMUNOMODULATORS DOES NOT AFFECT SKIN GRAFT REJECTION IN MICE

  1995cites this paper
• Modulation of nonspecific antimicrobial resistance of mice to Klebsiella pneumoniae septicemia by liposome-encapsulated muramyl tripeptide phosphatidylethanolamine and interferon-gamma alone or combined.

  1995cites this paper
• The past, present, and future uses of liposomes in treating infectious diseases.

  1995cites this paper
• Chemotherapy of experimental filariasis: enhancement of activity profile of ivermectin with immunomodulators.

  1994cites this paper
• Free and liposome-encapsulated immunomodulators stimulating the nonspecific resitance against bacterial infections

  1993cites this paper
• Introduction to Candida

  1993cites this paper
• Host defense system interactions with Candida.

  1992cites this paper
• Progress in antifungal chemotherapy

  1992cites this paper
• Free versus liposome-encapsulated muramyl tripeptide phosphatidylethanolamide in treatment of experimental Klebsiella pneumoniae infection

  1992cites this paper
• In Vivo Behavior of Liposomes: Interactions with the Mononuclear Phagocyte System and Implications for Drug Targeting

  1991cites this paper
• Immunomodulating peptides of natural and synthetic origin

  1991cites this paper
• Immunomodulating peptides of natural and synthetic origin.

  1991cites this paper
• Immunomodulatory activity of small peptides.

  1990cites this paper
• Immunomodulatory activity of small peptides.

  1990cites this paper
• Effect of Free and Liposome-Encapsulated MTP-PE on Klebsiella pneumoniae Infection in Mice

  1990cites this paper
• Efficacy of Interleukin-1β against Systemic Candida albicans Infections in Normal and Immunosuppressed Mice

  1990cites this paper
• Immunopharmacology

  1990cites this paper
• Immunomodulation by the new synthetic thiazole derivative tiprotimod. 3rd communication: influence on host resistance to microorganisms, tumors and on experimental immune disorders.

  1989cites this paper
• Influence of the immunostimulating substance tiprotimod on Candida albicans infection in relation to activation of macrophages.

  1989cites this paper
• Involvement of reactive oxygen metabolites in the candidacidal activity of human neutrophils stimulated by muramyl dipeptide or tumor necrosis factor.

  1989cites this paper
• Effect of free or liposome-encapsulated muramyl dipeptide on uptake and intracellular survival ofListeria monocytogenes in mouse peritoneal macrophages in vitro

  1989cites this paper
• Microbial synthesis of metabolites with antihypertensive activity: Aspects of fermentation derived inhibitors of angiotensin‐converting enzyme (ACE)

  1989cites this paper
• Efficacy of interleukin-1 beta against systemic Candida albicans infections in normal and immunosuppressed mice

  1989cites this paper
• Stimulation of non-specific resistance to infection by muroctasin.

  1988cites this paper
• Alternative delivery systems for peptides and proteins as drugs.

  1988cites this paper
• Targeting of Drugs

  1988cites this paper
• The Pharmacology of Lymphocytes

  1988cites this paper
• Future Prospects for Drug Design of Lymphocyte Modulators

  1988cites this paper
• Preparation and use of liposomes in the treatment of microbial infections.

  1988cites this paper
• Pragmatic Approaches to Delivery of Peptides and Proteins as Drugs

  1988cites this paper
• Liposomes in treatment of infectious diseases

  1987cites this paper
• Reticuloendothelial system phagocytic function in obstructive jaundice and its modification by a muramyl dipeptide analogue.

  1987cites this paper
• Anti-infectious activity of liposomal muramyl dipeptides in immunodeficient CBA/N mice

  1987cites this paper
• Liposomes as carriers of antimicrobial agents

  1987cites this paper
• Problems in Antifungal Chemotherapy

  1987cites this paper
• Prospects for Liposomes as Drug Carriers

  1987cites this paper
• Liposomes in Antimicrobial Therapy

  1986cites this paper
• Effect of an immunopotentiator on Aeromonas salmonicida infection in rainbow trout (Salmo gairdneri).

  1986cites this paper
• Curative properties of muramyl dipeptide in experimental Naegleria meningoencephalitis.

  1986cites this paper
• A study of the potential application of bleomycin entrapped within liposomes in the treatment of human cerebral gliomas

  1986cites this paper
• Recombinant interferon-gamma and chemotherapy with isoniazid and rifampicin in experimental murine tuberculosis.

  1986cites this paper
• Immunopotentiating Effect of N-Acetyl-Chito-Oligosaccharides

  1986cites this paper
• Effect of N‐Acetylchito‐Oligosaccharides on Activation of Phagocytes

  1986cites this paper
• Enhancement of Glucantime therapy of murine Leishmania donovani infection by a synthetic immunopotentiating compound (CP-46,665-1).

  1985cites this paper
• The potential use of liposome-mediated antiviral therapy

  1985cites this paper
• Prevention of oncogenic viral infections in mice with CGP 11637, a synthetic muramyl dipeptide analog

  1985cites this paper
• Prophylaxis of murine candidiasis via application of liposome-encapsulated amphotericin B and a muramyl dipeptide analog, alone and in combination

  1985cites this paper
• Synergistic effect of glucantime and a liposome-encapsulated muramyl dipeptide analog in therapy of experimental visceral leishmaniasis

  1985cites this paper
• Enhanced efficacy of liposome-encapsulated ribavirin against Rift Valley fever virus infection in mice

  1985cites this paper
• Human monocytes activated by immunomodulators in liposomes lyse herpesvirus-infected but not normal cells.

  1984cites this paper
• Protecting Effect of Chitin and Chitosan on Experimentally Induced Murine Candidiasis

  1984cites this paper
• Muraceins--muramyl peptides produced by Nocardia orientalis as angiotensin-converting enzyme inhibitors. I. Taxonomy, fermentation and biological properties.

  1984cites this paper
• Effect of stearoyl-N-acetylmuramyl-L-alanyl-D-isoglutamine on host resistance to Corynebacterium kutscheri infection in cortisone-treated mice.

  1984cites this paper
• Prophylaxis and treatment of experimental lung metastases in mice after treatment with liposome-encapsulated 6-O-stearoyl-N-acetylmuramyl-L-α-aminobutyryl-D-isoglutamine

  1984cites this paper
• Muraceins--muramyl peptides produced by Nocardia orientalis as angiotensin-converting enzyme inhibitors. II. Isolation and structure determination.

  1984cites this paper
• Muramyl peptides: Immunomodulators, sleep factors, and vitamins

  1984cites this paper
• Liposomes in immunology

  1984cites this paper
• Preservation of multilamellar lipid vesicles (liposomes) for ultrastructural studies.

  1983cites this paper
• Lysis of herpesvirus-infected cells by macrophages activated with free or liposome-encapsulated lymphokine produced by a murine T cell hybridoma

  1983cites this paper
• Enhanced activity of streptomycin and chloramphenicol against intracellular Escherichia coli in the J774 macrophage cell line mediated by liposome delivery

  1983cites this paper